News
Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in ...
The Diffuse Large B-cell Lymphoma (DLBCL) market is witnessing significant growth, driven by advancements in targeted immunotherapies like CAR-T cell therapy and bispecific antibodies. These therapies ...
Veeva Systems (NYSE: VEEV) today announced Boehringer Ingelheim is the latest top 20 biopharma to standardize customer data ...
Veeva Systems (NYSE: VEEV) today announced that Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results